CD25/Interleukin-2Ra Monoclonal Antibody (PE)

CD25, also known as interleukin-2 receptor ? (IL-2R?), is a transmembrane glycoprotein.{60243} It is composed of two domains, D1 and D2, and associates with the CD122/IL-2? and CD132/IL-2?c subunits to form the heterotrimeric IL-2 receptor. CD25 is expressed in activated T and B cells, regulatory T cells, and lymphokine-activated killer (LAK) cells.{60244,60245,6128} Activation of IL-2R on T cells increases the expression of CD25 and leads to T cell proliferation and differentiation, as well as activation-induced T cell death.{60245,6128} ILR2A expression and CD25 protein levels in bone marrow are increased in patients with acute myeloid leukemia (AML) and associated with poor prognosis.{60245} SNPs in ILR2A and elevated serum levels of a soluble form of CD25 are associated with an increased risk of Graves' disease.{60246} Cayman’s CD25/Interleukin-2R? Monoclonal Antibody (PE) (Clone 143-13) is composed of a CD25 monoclonal antibody conjugated to phycoerythrin (PE) and can be used for flow cytometry (FC), immunocytochemistry (ICC), and immunohistochemistry (IHC) applications.